

## Publications Oncostat 2015

---

1. Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzebec P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. *Eur Urol.* 2015;68:228-35. PubMed PMID: 24837187.
2. Allodji RS, Schwartz B, Veres C, Haddy N, Rubino C, Le Deley MC, Labbé M, Diop F, Jackson A, Dayet F, Benabdennebi A, Llanas D, Vu Bezin J, Chavaudra J, Lefkopoulos D, Deutsch E, Oberlin O, de Vathaire F, Diallo I. Risk of Subsequent Leukemia After a Solid Tumor in Childhood: Impact of Bone Marrow Radiation Therapy and Chemotherapy. *Int J Radiat Oncol Biol Phys.* 2015;93:658-67. PubMed PMID: 26461008.
3. Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, Andre F. Precision medicine for metastatic breast cancer--limitations and solutions. *Nat Rev Clin Oncol.* 2015;12(12):693-704. Epub 2015/07/22. doi: 10.1038/nrclinonc.2015.123. PubMed PMID: 26196250.
4. Benadjaoud MA, de Vathaire F, Blanchard P, Cardot H. In reply to Alber and Sohn. *International journal of radiation oncology, biology, physics.* 2015;91(3):679. Epub 2015/02/15. doi: 10.1016/j.ijrobp.2014.11.010. PubMed PMID: 25680607.
5. Billaux M, Borget I, Prognon P, Pineau J, Martelli N. Innovative medical devices and hospital decision making: a study comparing the views of hospital pharmacists and physicians. *Aust Health Rev.* 2015. PubMed PMID: 26342894.
6. Blanchard P, Bakkour M, De Crevoisier R, Levy A, Baumert H, Patard JJ, Wibault P, Fizazi K, Bossi A. Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy. *Urologic oncology.* 2015;33(3):108 e15-20. Epub 2014/09/02. doi: 10.1016/j.urolonc.2014.07.020. PubMed PMID: 25176583.
7. Blanchard P, Bourhis J, Lacas B, Le Teuff G, Michiels S, Pignon JP. [Individual patient data meta-analyses of randomized trials for the treatment of non-metastatic head and neck squamous cell carcinomas: Principles, results and perspectives]. *Cancer Radiother.* 2015;19(3):198-204; quiz 28-9, 33. Epub 2015/04/11. doi: 10.1016/j.canrad.2014.12.009. PubMed PMID: 25858708.
8. Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP, Group M-NC. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. *The Lancet Oncology.* 2015;16(6):645-55. Epub 2015/05/11. doi: 10.1016/S1470-2045(15)70126-9. PubMed PMID: 25957714.
9. Bölling T, Braun-Munzinger G, Burdach S, Calaminus G, Craft A, Delattre O, Deley MC, Dirksen U, Dockhorn-Dworniczak B, Dunst J, Engel S, Faldum A, Fröhlich B,

Gadner H, Göbel U, Gosheger G, Harges J, Hawkins DS, Hjorth L, Hoffmann C, Kovar H, Kruseova J, Ladenstein R, Leuschner I, Lewis IJ, Oberlin O, Paulussen M, Potratz J, Ranft A, Rössig C, Rübe C, Sauer R, Schober O, Schuck A, Timmermann B, Tirode F, van den Berg H, van Valen F, Vieth V, Willich N, Winkelmann W, Whelan J, Womer RB. Development of curative therapies for Ewing sarcomas by interdisciplinary cooperative groups in Europe. *Klin Padiatr.* 2015;227:108-15. PubMed PMID: 25985445.

10. Bonastre J, Marguet S, Lueza B, Michiels S, Delaloge S, Saghatchian M. Reply to V.P. Retel et al, D. Gauchan et al, and C. Rahilly-Tierney et al. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2015;33(14):1629-30. Epub 2015/04/08. doi: 10.1200/JCO.2014.60.5568. PubMed PMID: 25847933.
11. Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, Bardet S, Leenhardt L, Bastie D, Schwartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Kelly A, Toubert ME, Leboulleux S, Journeau F, Benhamou E, Schlumberger M. Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. *J Clin Oncol.* 2015;33:2885-92. PubMed PMID: 26240230.
12. Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuutila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. *Cochrane Database Syst Rev.* 2015;3:CD011430. PubMed PMID: 25730344.
13. Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Pappas V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. *Clin Infect Dis.* 2015;60:1262-8. PubMed PMID: 25567330.
14. Chouaid C, Borget I, Braun E, Bazil M, Schaetz D, Rémuzat C, Toumi M. French Health Technology Assessment Of Antineoplastic Drugs Indicated In The Treatment Of Solid Tumours: Perspective For Future Trends. *Value Health.* 2015;18:A489. PubMed PMID: 26532744.
15. Chouaïd C, Crequit P, Borget I, Vergnenegre A. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. *Clinicoecon Outcomes Res.* 2015;7:9-15. PubMed PMID: 25548525.
16. Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schwartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M. Vandetanib for the treatment of advanced medullary

thyroid cancer outside a clinical trial: results from a French cohort. *Thyroid*. 2015;25:386-91. PubMed PMID: 25627619.

17. Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet*. 2015;386:1353-61. PubMed PMID: 26211824.
18. Dartois L, Gauthier E, Heitzmann J, Baglietto L, Michiels S, Mesrine S, Boutron-Ruault MC, Delaloge S, Ragusa S, Clavel-Chapelon F, Fagherazzi G. A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort. *Breast cancer research and treatment*. 2015;150(2):415-26. Epub 2015/03/07. doi: 10.1007/s10549-015-3321-7. PubMed PMID: 25744293.
19. de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussière J. Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al. *Ann Oncol*. 2015;26:2196-7. PubMed PMID: 26193885.
20. de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussière J. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. *Ann Oncol*. 2015;26:987-91. PubMed PMID: 25688058.
21. Deutsch E, Le Péchoux C, Faivre L, Rivera S, Tao Y, Pignon JP, Angokai M, Bahleda R, Deandreis D, Angevin E, Hennequin C, Besse B, Levy A, Soria JC. Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. *Ann Oncol*. 2015;26:1223-9. PubMed PMID: 25701455.
22. Di Giannatale A, Frezza AM, Le Deley MC, Marec-Bérard P, Benson C, Blay JY, Bui B, Judson I, Oberlin O, Whelan J, Gaspar N. Primary cutaneous and subcutaneous Ewing sarcoma. *Pediatr Blood Cancer*. 2015;62:1555-61. PubMed PMID: 25894676.
23. Diouf M, Bonnetain F, Barbare JC, Bouche O, Dahan L, Paoletti X, Filleron T. Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. *The oncologist*. 2015;20(1):62-71. Epub 2014/12/30. doi: 10.1634/theoncologist.2014-0175. PubMed PMID: 25542450; PMCID: 4294602.
24. dos Santos MA, Pignon JP, Blanchard P, Lefeuvre D, Levy A, Touat M, Louvel G, Dhermain F, Soria JC, Deutsch E, Le Teuff G. Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. *Journal of neuro-oncology*. 2015;123(2):307-14. Epub 2015/05/16. doi: 10.1007/s11060-015-1802-5. PubMed PMID: 25975195.
25. Doussau A, Thiebaut R, Georger B, Schoffski P, Floquet A, Le Deley MC, Mathoulin-Pelissier S, Rizzo E, Fumoleau P, Le Tourneau C, Paoletti X. A new approach to integrate toxicity grade and repeated treatment cycles in the analysis

and reporting of phase I dose-finding trials. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2015;26(2):422-8. Epub 2014/11/19. doi: 10.1093/annonc/mdu523. PubMed PMID: 25403589.

26. Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsy P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*. 2015;386:1341-52. PubMed PMID: 26211827.
27. Drubay D, Caer-Lorho S, Laroche P, Laurier D, Rage E. Mortality from Circulatory System Diseases among French Uranium Miners: A Nested Case-Control Study. *Radiation research*. 2015;183(5):550-62. Epub 2015/03/26. doi: 10.1667/RR13834.1. PubMed PMID: 25807316.
28. Early Breast Cancer Trialists' Collaborative G, Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet*. 2015;386(10001):1353-61. Epub 2015/07/28. doi: 10.1016/S0140-6736(15)60908-4. PubMed PMID: 26211824.
29. Early Breast Cancer Trialists' Collaborative G, Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsy P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*. 2015;386(10001):1341-52. Epub 2015/07/28. doi: 10.1016/S0140-6736(15)61074-1. PubMed PMID: 26211827.
30. Ezzalfani M, Dugue A, Mollevi C, Pulido M, Bonnetain F, Filleron T, Gal J, Gauthier M, Le Deley MC, Le Tourneau C, Medioni J, Nguyen JM, Chabaud S, Teixeira L, Thivat E, You B, Kramar A, Paoletti X. [The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]. *Bull Cancer*. 2015;102(1):73-82. Epub 2015/01/23. doi: 10.1016/j.bulcan.2014.10.001. PubMed PMID: 25609488.
31. Faron M, Pignon JP, Malka D, Bourredjem A, Douillard JY, Adenis A, Elias D, Bouché O, Ducreux M. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. *Eur J Cancer*. 2015;51:166-76. PubMed PMID: 25465185.
32. Foulon S, Greacen T, Pasquet B, Dugravier R, Saias T, Guedeney N, Guedeney A, Tubach F, Group CS. Predictors of Study Attrition in a Randomized Controlled Trial Evaluating a Perinatal Home-Visiting Program with Mothers with Psychosocial Vulnerabilities. *PLoS One*. 2015;10(11):e0142495. Epub 2015/11/12. doi: 10.1371/journal.pone.0142495. PubMed PMID: 26554839; PMCID: 4640666.
33. Foulon S, Pingault JB, Larroque B, Melchior M, Falissard B, Cote SM. Developmental predictors of inattention-hyperactivity from pregnancy to early

childhood. PLoS One. 2015;10(5):e0125996. Epub 2015/05/06. doi: 10.1371/journal.pone.0125996. PubMed PMID: 25938453; PMCID: 4418828.

34. Gajda D, Kiegiel K, Zakrzewska-Koltuniewicz G, Chajduk E, Bartosiewicz I, Wolkowicz S. Mineralogy and uranium leaching of ores from Triassic Peribaltic sandstones. *J Radioanal Nucl Chem.* 2015;303:521-9. PubMed PMID: 26224979.
35. Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, Delattre O, Paulussen M, Picci P, Sundby Hall K, van den Berg H, Ladenstein R, Michon J, Hjorth L, Judson I, Luksch R, Bernstein ML, Marec-Bérard P, Brennan B, Craft AW, Womer RB, Juergens H, Oberlin O. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. *J Clin Oncol.* 2015;33:3036-46. PubMed PMID: 26304893.
36. Gorphe P, Blanchard P, Breuskin I, Temam S, Tao Y, Janot F. Vocal fold mobility as the main prognostic factor of treatment outcomes and survival in stage II squamous cell carcinomas of the glottic larynx. *The Journal of laryngology and otology.* 2015;129(9):903-9. Epub 2015/07/24. doi: 10.1017/S002221511500184X. PubMed PMID: 26201253.
37. Gorphe P, Blanchard P, Temam S, Janot F. Influence of the vocal cord mobility in salvage surgery after radiotherapy for early-stage squamous cell carcinoma of the glottic larynx. *Eur Arch Otorhinolaryngol.* 2015;272(10):3013-8. Epub 2014/09/15. doi: 10.1007/s00405-014-3286-x. PubMed PMID: 25218197.
38. Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delalogue S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). *Ann Oncol.* 2015;26:2505-6. PubMed PMID: 26467471.
39. Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delalogue S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pelissier S, Bellera C, Dabakuyo-Yonli TS. Definition for the Assessment of Time-to-event Endpoints in Cancer Trials I. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)dagger. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.* 2015;26(5):873-9. Epub 2015/03/01. doi: 10.1093/annonc/mdv106. PubMed PMID: 25725046.

40. Grünewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, Mirabeau O, Cidre-Aranaz F, Tirode F, Zaidi S, Perot G, Jonker AH, Lucchesi C, Le Deley MC, Oberlin O, Marec-Bérard P, Véron AS, Reynaud S, Lapouble E, Boeva V, Rio Frio T, Alonso J, Bhatia S, Pierron G, Cancel-Tassin G, Cussenot O, Cox DG, Morton LM, Machiela MJ, Chanock SJ, Charnay P, Delattre O. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. *Nat Genet.* 2015;47:1073-8. PubMed PMID: 26214589.
41. Guichard M, D'Andon A, Rumeau Pichon C, Borget I. The Use of Indirect Comparisons in Medicines Evaluation for their Access To Reimbursement by the Has. *Value Health.* 2015;18:A719. PubMed PMID: 26534028.
42. Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Lorient Y, Duvillard P, Chougnat CN, Déandréis D, Schlumberger M, Borget I, Ducreux M, Baudin E. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. *Endocr Relat Cancer.* 2015;22:289-98. PubMed PMID: 25770151.
43. Huynh M, Poumeyrol S, Pignon C, Le Teuff G, Zilberstein L. Intramuscular administration of alfaxalone for sedation in rabbits. *Vet Rec.* 2015;176:255. PubMed PMID: 25433053.
44. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. *Ann Oncol.* 2015;26:1128-33. PubMed PMID: 25795198.
45. Jacob J, Heymann S, Borget I, Dumas I, Riahi E, Maroun P, Ezra P, Roberti E, Rivera S, Deutsch E, Bourcier C. Dosimetric Effects of the Interfraction Variations during Whole Breast Radiotherapy: A Prospective Study. *Front Oncol.* 2015;5:199. PubMed PMID: 26442211.
46. Joskin J, de Baere T, Auperin A, Tselikas L, Guiu B, Farouil G, Boige V, Malka D, Leboulleux S, Ducreux M, Baudin E, Deschamps F. Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. *Cardiovasc Intervent Radiol.* 2015;38:372-80. PubMed PMID: 24873919.
47. Jourdain A, Auperin A, Minard-Colin V, Aladjidi N, Zsiros J, Coze C, Gandemer V, Bertrand Y, Leverger G, Bergeron C, Michon J, Patte C. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study. *Haematologica.* 2015;100:810-7. PubMed PMID: 25724577.
48. Kapetanakis NI, Uzan C, Jimenez-Pailhes AS, Gouy S, Bentivegna E, Morice P, Caron O, Gourzones-Dmitriev C, Le Teuff G, Busson P. Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival. *Oncotarget.* 2015;6:36815-24. PubMed PMID: 26416421.

49. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. *Oncotarget*. 2015;6:14139-52. PubMed PMID: 25944621.
50. Le Teuff G, Abrahamowicz M, Wynant W, Binquet C, Moreau T, Quantin C. Flexible modeling of disease activity measures improved prognosis of disability progression in relapsing-remitting multiple sclerosis. *J Clin Epidemiol*. 2015;68:307-16. PubMed PMID: 25541382.
51. Le Tourneau C, Belin L, Paoletti X, Bieche I, Kamal M. Precision medicine: lessons learned from the SHIVA trial - Authors' reply. *The Lancet Oncology*. 2015;16(16):e581-2. Epub 2015/12/19. doi: 10.1016/S1470-2045(15)00455-6. PubMed PMID: 26678200.
52. Le Tourneau C, Delord JP, Goncalves A, Gavaille C, Dubot C, Isambert N, Campone M, Tredan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bieche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X, investigators S. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. *The Lancet Oncology*. 2015;16(13):1324-34. Epub 2015/09/08. doi: 10.1016/S1470-2045(15)00188-6. PubMed PMID: 26342236.
53. Lepoutre-Lussey C, Caramella C, Bidault F, Déandreis D, Berdelou A, Al Ghuzlan A, Hartl D, Borget I, Gimenez-Roqueplo AP, Dumont F, Deschamps F, Nascimento C, Lumbroso J, Guillaud Bataille M, Schlumberger M, Baudin E, Leboulleux S. Screening in asymptomatic SDHx mutation carriers: added value of <sup>18</sup>F-FDG PET/CT at initial diagnosis and 1-year follow-up. *Eur J Nucl Med Mol Imaging*. 2015;42:868-76. PubMed PMID: 25676472.
54. Levy A, Azria D, Pignon JP, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Leclercq J, Juzyna B, Ezra P, Lemanski C, Deutsch E. Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. *Radiother Oncol*. 2015;114:415-6. PubMed PMID: 25769380.
55. Levy A, Leboulleux S, Lepoutre-Lussey C, Baudin E, Ghuzlan AA, Hartl D, Deutsch E, Deandreis D, Lumbroso J, Tao Y, Schlumberger M, Blanchard P. (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. *Oral oncology*. 2015;51(4):370-5. Epub 2015/01/18. doi: 10.1016/j.oraloncology.2014.12.014. PubMed PMID: 25595614.

56. Levy A, Martelli H, Fayeche C, Minard-Colin V, Dumas I, Gensse MC, Le Deley MC, Oberlin O, Haie-Meder C. Late toxicity of brachytherapy after female genital tract tumors treated during childhood: Prospective evaluation with a long-term follow-up. *Radiother Oncol.* 2015;117:206-12. PubMed PMID: 26463838.
57. Levy C, Allouache D, Lacroix J, Dugue AE, Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, Dieras V, Kirova Y, Campana F, Le Rhun E, Gras L, Bachelot T, Sunyach MP, Hrab I, Geffrelet J, Gunzer K, Constans JM, Grellard JM, Clarisse B, Paoletti X. REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.* 2015;26(11):2359. Epub 2015/10/28. doi: 10.1093/annonc/mdv386. PubMed PMID: 26504187.
58. Li J, Drubay D, Michiels S, Gautheret D. Mining the coding and non-coding genome for cancer drivers. *Cancer letters.* 2015;369(2):307-15. Epub 2015/10/04. doi: 10.1016/j.canlet.2015.09.015. PubMed PMID: 26433158.
59. Li J, Poursat MA, Drubay D, Motz A, Saci Z, Morillon A, Michiels S, Gautheret D. A Dual Model for Prioritizing Cancer Mutations in the Non-coding Genome Based on Germline and Somatic Events. *PLoS Comput Biol.* 2015;11:e1004583. PubMed PMID: 26588488.
60. Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, Quinkler M, Chabre O, Bala M, Tabarin A, Beuschlein F, Vezzosi D, Deutschbein T, Borson-Chazot F, Hermsen I, Stell A, Fottner C, Leboulleux S, Hahner S, Mannelli M, Berruti A, Haak H, Terzolo M, Fassnacht M, Baudin E. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. *Ann Oncol.* 2015;26:2119-25. PubMed PMID: 26392430.
61. Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. *Lancet HIV.* 2015;2:e335-43. PubMed PMID: 26423376.
62. Luporsi E, Bellocq JP, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Cremoux P, Fina F, Gauchez AS, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V, Kassab-Chahmi D. [uPA/PAI-1, Oncotype DX™, MammaPrint®]. Prognosis and predictive values for clinical utility in breast cancer management]. *Bull Cancer.* 2015;102:719-29. PubMed PMID: 26235416.
63. M'Kacher R, Girinsky T, Colicchio B, Ricoul M, Dieterlen A, Jeandidier E, Heidingsfelder L, Cuceu C, Shim G, Frenzel M, Lenain A, Morat L, Bourhis J, Hempel WM, Koscielny S, Paul JF, Carde P, Sabatier L. Telomere shortening: a new prognostic factor for cardiovascular disease post-radiation exposure. *Radiat Prot Dosimetry.* 2015;164:134-7. PubMed PMID: 25274533.



64. Mamelie E, Borget I, Leboulleux S, Mirghani H, Suárez C, Pellitteri PK, Shaha AR, Hamoir M, Robbins KT, Khafif A, Rodrigo JP, Silver CE, Rinaldo A, Ferlito A, Hartl DM. Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review. *Eur Arch Otorhinolaryngol.* 2015;272:1577-86. PubMed PMID: 25022716.
65. Marous M, Bieche I, Paoletti X, Alt M, Razak AR, Stathis A, Kamal M, Le Tourneau C. Designs of preoperative biomarkers trials in oncology: a systematic review of the literature. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.* 2015;26(12):2419-28. Epub 2015/09/16. doi: 10.1093/annonc/mdv378. PubMed PMID: 26371283.
66. Martelli N, Billaux M, Borget I, Pineau J, Prognon P, van den Brink H. INTRODUCTION OF INNOVATIVE MEDICAL DEVICES AT FRENCH UNIVERSITY HOSPITALS: AN OVERVIEW OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT INITIATIVES. *Int J Technol Assess Health Care.* 2015;31:12-8. PubMed PMID: 25991072.
67. Martelli N, Devaux C, van den Brink H, Pineau J, Prognon P, Borget I. A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty. *PLoS ONE.* 2015;10:e0144892. PubMed PMID: 26661078.
68. Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, Kammerer SF, Rioux-Leclerc N, Hasmim M, Ferlicot S, Baud V, Mejean A, Mole DR, Richard S, Eggermont AM, Albiges L, Mami-Chouaib F, Escudier B, Chouaib S. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. *Eur Urol.* 2015. PubMed PMID: 26707870.
69. Michot JM, Mazon R, Danu A, Lazarovici J, Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, Bosq J, Carde P, Koscielny S, De Botton S, Ferme C, Girinsky T, Ribrag V. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. *Eur J Cancer.* 2015;51:2386-95. PubMed PMID: 26254810.
70. Minacori R, Bonastre J, Lueza B, Marguet S, Levy P. How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models. *Value Health.* 2015;18:A704. PubMed PMID: 26533946.
71. Minard-Colin V, Brugières L, Reiter A, Cairo MS, Gross TG, Woessmann W, Burkhardt B, Sandlund JT, Williams D, Pillon M, Horibe K, Auperin A, Le Deley MC, Zimmerman M, Perkins SL, Raphael M, Lamant L, Klapper W, Mussolin L, Poirel HA, Macintyre E, Damm-Welk C, Rosolen A, Patte C. Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. *J Clin Oncol.* 2015;33:2963-74. PubMed PMID: 26304908.
72. Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, Hartl DM, Lacau St Guily J. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials,

critical issues and perspectives. *International journal of cancer*. 2015;136(7):1494-503. Epub 2014/03/14. doi: 10.1002/ijc.28847. PubMed PMID: 24622970.

73. Moignier A, Broggio D, Derreumaux S, Beaudre A, Girinsky T, Paul JF, Drubay D, Lefkopoulos D, Franck D, Aubert B, Deutsch E, Bourhis J. Coronary stenosis risk analysis following Hodgkin lymphoma radiotherapy: A study based on patient specific artery segments dose calculation. *Radiother Oncol*. 2015;117(3):467-72. Epub 2015/08/19. doi: 10.1016/j.radonc.2015.07.043. PubMed PMID: 26277431.
74. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey C, Mirghani H, Baudin E, Schlumberger M, Leboulleux S. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. *Thyroid*. 2015;25:437-44. PubMed PMID: 25633259.
75. Olivier Bosset P, Neuzillet Y, Paoletti X, Molinie V, Botto H, Leuret T. Long-term follow-up of TaG1 non-muscle-invasive bladder cancer. *Urologic oncology*. 2015;33(1):20 e1-7. Epub 2014/10/06. doi: 10.1016/j.urolonc.2014.09.001. PubMed PMID: 25282704.
76. Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, Ngo-Camus M, Planchard D, Soria JC, Besse B, Farace F. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. *Ann Oncol*. 2015;26:1408-15. PubMed PMID: 25846554.
77. Palussiere J, Lagarde P, Aupérin A, Deschamps F, Chomy F, de Baere T. Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer: results of eight years' experience in 87 patients from two centers. *Cardiovasc Intervent Radiol*. 2015;38:160-6. PubMed PMID: 25394595.
78. Paoletti X, Asselain B, Kamal M, Servant N, Huppe P, Bieche I, Le Tourneau C. Design and statistical principles of the SHIVA trial. *Chinese clinical oncology*. 2015;4(3):32. Epub 2015/09/27. doi: 10.3978/j.issn.2304-3865.2015.02.02. PubMed PMID: 26408299.
79. Paoletti X, Doussau A, Ezzalfani M, Rizzo E, Thiebaut R. Dose finding with longitudinal data: simpler models, richer outcomes. *Stat Med*. 2015;34(22):2983-98. Epub 2015/06/26. doi: 10.1002/sim.6552. PubMed PMID: 26109523.
80. Paoletti X, Ezzalfani M, Le Tourneau C. Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2015;26(9):1808-12. Epub 2015/06/20. doi: 10.1093/annonc/mdv266. PubMed PMID: 26088197; PMCID: 4551156.
81. Patrikidou A, Brureau L, Casenave J, Albiges L, Di Palma M, Patard JJ, Baumert H, Blanchard P, Bossi A, Kitikidou K, Massard C, Fizazi K, Blanchet P, Loriot Y. Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. *Urologic oncology*. 2015;33(5):202

e9-17. Epub 2015/03/10. doi: 10.1016/j.urolonc.2015.01.022. PubMed PMID: 25746940.

82. Perrier L, Heinz D, Baffert S, Zou Z, Durand Zaleski I, Rouleau E, Wang Q, Haddad V, Bringuier P, Merlio J, Caumont C, Lacroix L, Marino P, Borget I. Cost Of Genome Analysis: The Sanger Sequencing Method. *Value Health*. 2015;18:A353. PubMed PMID: 26531995.
83. Rage E, Caer-Lorho S, Drubay D, Ancelet S, Laroche P, Laurier D. Mortality analyses in the updated French cohort of uranium miners (1946-2007). *International archives of occupational and environmental health*. 2015;88(6):717-30. Epub 2014/11/21. doi: 10.1007/s00420-014-0998-6. PubMed PMID: 25410273.
84. Raynaud C, Greillier L, Mazieres J, Monnet I, Mastroianni B, Robinet G, Fraboulet G, Dixmier A, Berard H, Lamy R, Letreut J, Lena H, Oliviero G, Botta S, Vergnenegre A, Borget I, Chouaid C. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). *BMC Cancer*. 2015;15:857. PubMed PMID: 26546402.
85. Ribassin-Majed L, Hill C. Trends in tobacco-attributable mortality in France. *Eur J Public Health*. 2015;25(5):824-8. Epub 2015/05/11. doi: 10.1093/eurpub/ckv078. PubMed PMID: 25958238.
86. Ribassin-Majed L, Hill C, Lounes R. Efficacy of vaccination against HPV infection to prevent cervical cancer in France. *Public Health*. 2015;129(1):78-81. Epub 2014/12/30. doi: 10.1016/j.puhe.2014.11.005. PubMed PMID: 25544659.
87. Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, Campbell S, Elson P, Koscielny S, Lopatin M, Svedman C, Martini JF, Williams JA, Verkarre V, Radulescu C, Neuzillet Y, Hemmerlé I, Timsit MO, Tsiatis AC, Bonham M, Lebret T, Mejean A, Escudier B. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. *Lancet Oncol*. 2015;16:676-85. PubMed PMID: 25979595.
88. Riviere MK, Le Tourneau C, Paoletti X, Dubois F, Zohar S. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2015;26(4):669-74. Epub 2014/11/19. doi: 10.1093/annonc/mdu516. PubMed PMID: 25403591.
89. Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, Baran R. Nail toxicities induced by systemic anticancer treatments. *Lancet Oncol*. 2015;16:e181-9. PubMed PMID: 25846098.
90. Rondeau V, Pignon JP, Michiels S, Group M-Nc. A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer. *Stat Methods Med Res*. 2015;24(6):711-29. Epub 2011/10/26. doi: 10.1177/0962280211425578. PubMed PMID: 22025414.
91. Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological

Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. *JAMA Oncol.* 2015;1(4):448-54. Epub 2015/07/17. doi: 10.1001/jamaoncol.2015.0830. PubMed PMID: 26181252.

92. Schneider D, Bianchini G, Horgan D, Michiels S, Witjes W, Hills R, Plun-Favreau J, Brand A, Lawler M. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. *Public Health Genomics.* 2015;18:349-58. PubMed PMID: 26571110.
93. Scotte F, Martelli N, Vainchtock A, Borget I. The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France. *Adv Ther.* 2015;32:138-47. PubMed PMID: 25716549.
94. Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, Morabito M, Met E, Debord C, Benayoun E, Nloga AM, Fenaux P, Braun T, Willekens C, Quesnel B, Adès L, Fontenay M, Rameau P, Droin N, Koscielny S, Solary E. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. *Blood.* 2015;125:3618-26. PubMed PMID: 25852055.
95. Squifflet P, Michiels S, Siegel D, Vij R, Jagannath S, Saad ED, Rajangam K, Ro SK, Buyse M. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk.* 2015;15:680-6. PubMed PMID: 26482107.
96. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA.* 2015;313:1657-65. PubMed PMID: 25919529.
97. Strullu M, Thomas C, Le Deley MC, Chevance A, Kanold J, Bertrand Y, Jubert C, Dalle JH, Paillard C, Baruchel A, Lamant L, Michel G, Brugières L. Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC. *Bone Marrow Transplant.* 2015;50:795-801. PubMed PMID: 25822227.
98. Sze H, Blanchard P, Ng WT, Pignon JP, Lee AW. Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies. *Hematology/oncology clinics of North America.* 2015;29(6):1107-22. Epub 2015/11/17. doi: 10.1016/j.hoc.2015.07.004. PubMed PMID: 26568551.
99. Tejera-Vaquerizo A, Nagore E, Puig S, Robert C, Saiag P, Martín-Cuevas P, Gallego E, Herrera-Acosta E, Aguilera J, Malveyh J, Carrera C, Cavalcanti A, Rull R, Vilalta-Solsona A, Lannoy E, Boutros C, Benannoune N, Tomasic G, Aegerte P, Vidal-Sicart S, Palou J, Alos LL, Requena C, Traves V, Pla Á, Bolumar I, Soriano V, Guillén C, Herrera-Ceballos E. Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. *Eur J Cancer.* 2015;51:1780-93. PubMed PMID: 26072362.

100. Tierney JF, Pignon JP, Gueffier F, Clarke M, Askie L, Vale CL, Burdett S. How individual participant data meta-analyses have influenced trial design, conduct, and analysis. *J Clin Epidemiol.* 2015;68:1325-35. PubMed PMID: 26186982.
101. Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, Brambilla EM. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. *J Clin Oncol.* 2015;33:3439-46. PubMed PMID: 25918286.
102. Tselikas L, Joskin J, Roquet F, Farouil G, Dreuil S, Hakimé A, Teriitehau C, Auperin A, de Baere T, Deschamps F. Percutaneous bone biopsies: comparison between flat-panel cone-beam CT and CT-scan guidance. *Cardiovasc Intervent Radiol.* 2015;38:167-76. PubMed PMID: 24627161.
103. Vale CL, Rydzewska LH, Rovers MM, Emberson JR, Gueyffier F, Stewart LA. Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. *BMJ.* 2015;350:h1088. PubMed PMID: 25747860.
104. van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. *Eur J Cancer.* 2015;51:2453-64. PubMed PMID: 26271204.